It has been shown that miR-216a-3p downregulates MAPK14 expression and inhibits the activation of the MEK/ERK and ATF2 signaling pathways, enhancing HCC cells’ sensitivity to sorafenib [71]. This evidence concerns the gene ATF2 and hepatocellular carcinoma.